David Yi

David Yi

ID: 1b839951-2619-30fb-68c4

/

Claimed Record

/

Organization: Norton Rose Fulbright

Change in utility law not a factor in s. 8 damages

Pharma in Brief · April 10, 2018

Section 8 liability offset by patent infringement in esomeprazole case

Pharma in Brief · March 27, 2018

Ontario Superior Court denies pleading amendments based on Supreme Court of Canada’s rejection of promise doctrine in ramipril damages action

Pharma in Brief · February 15, 2018

FCA Limits Scope of Dutch Industries and Declines to Invalidate Patent on the Basis of Administrative Non-Compliance with Patent Act in latanoprost s. 8 case

Pharma in Brief · October 12, 2017

Apotex disentitled to section 8 recovery on the basis of patent infringement in omeprazole case

Pharma in Brief · September 17, 2017

Practice Areas

Health Care and Life Sciences

Jurisdictions